Beijing Aosaikang Pharmaceutical (002755) Fundamentals 2026 — P/E 46.7x, Revenue Analysis | SniperIQ
Beijing Aosaikang Pharmaceutical (002755) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥12.2B, trading at ¥13.17 on the SHZ. This SniperIQ fundamentals page covers Beijing Aosaikang Pharmaceutical's valuation (P/E 46.7x, P/B 3.7x), profitability (net margin 15.2%), revenue (¥1.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Beijing Aosaikang Pharmaceutical's market cap?
Beijing Aosaikang Pharmaceutical (002755) has a market capitalization of approximately ¥12.2B, trading at ¥13.17 on the SHZ. Market cap moves with the live share price.
What is Beijing Aosaikang Pharmaceutical's P/E ratio?
Beijing Aosaikang Pharmaceutical's trailing twelve-month P/E ratio is 46.7x, with a price-to-book (P/B) of 3.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Beijing Aosaikang Pharmaceutical?
Beijing Aosaikang Pharmaceutical runs a net profit margin of 15.2%, a gross margin of 80.6%, and an operating margin of 16.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Beijing Aosaikang Pharmaceutical generate?
Beijing Aosaikang Pharmaceutical reported revenue of ¥1.8B for fiscal year 2025, with net income of ¥237M and earnings per share (EPS) of 0.25. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Beijing Aosaikang Pharmaceutical pay a dividend?
Beijing Aosaikang Pharmaceutical offers a trailing dividend yield of about 0.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Beijing Aosaikang Pharmaceutical financially healthy?
Beijing Aosaikang Pharmaceutical carries a debt-to-equity ratio of 0.00x and a current ratio of 2.73x, with a market beta of 0.14. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Beijing Aosaikang Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Beijing Aosaikang Pharmaceutical (002755) the key facts are: market cap ¥12.2B, P/E 46.7x, revenue ¥1.8B, 52-week range 12.06-29. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Beijing Aosaikang Pharmaceutical's full fundamentals live
Get Beijing Aosaikang Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.